An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)
TREASURE
A Non-interventional Prospective Observational Study to Understand the Usage Pattern of Ticagrelor in Indian Patients With Acute Coronary Syndrome.
2 other identifiers
observational
3,000
1 country
31
Brief Summary
The TREASURE observational study is designed to address the need to understand the usage pattern of Ticagrelor in real life scenario in large number of ACS (Acute Coronary Syndrome) patients in India. The aim of this national study is to understand the usage pattern (including the duration of treatment) of Ticagrelor in various ACS patient population undergoing PCI (Percutaneous Coronary Intervention), CABG (Coronary Artery Bypass Graft) or medical management in a real-life setting in India.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2015
Typical duration for all trials
31 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 31, 2015
CompletedFirst Posted
Study publicly available on registry
April 3, 2015
CompletedStudy Start
First participant enrolled
April 27, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 24, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 24, 2017
CompletedJune 25, 2018
June 1, 2018
2.2 years
March 31, 2015
June 21, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Usage pattern of Ticagrelore in real life setting
Assessing the proportion of enrolled patients with different types of ACS namely, STEMI (ST segment Elevation Myocardial Infarction), NSTEMI (Non-ST segment Elevation Myocardial Infarction) and UA (Unstable Angina)
48 Weeks
Usage pattern of Ticagrelore
Assessing the proportion of patients with different types of ACS management namely, PCI, CABG and Medical Management
48 Weeks
Secondary Outcomes (1)
Frequency of various risk factors
48 Weeks
Study Arms (1)
one arm
patients on Ticagrelor
Eligibility Criteria
Male/female with Acute Coronary Syndrome on Ticagrelor on discharge or ≤ 1month
You may qualify if:
- Written informed consent has been provided.
- Aged 18 years or older.
- Male/female with ACS on Ticagrelor on discharge or ≤ 1month.
- Patient underwent PCI, CABG or MM (Medical Management) for ACS.
- Diagnosis of STEMI, NSTEMI or UA
You may not qualify if:
- Patients with medical history of intracranial hemorrhage
- All those patients who are not fit to receive Ticagrelor as per the latest prescribing information
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (31)
Research Site
Hyderabad, Andhra Pradesh, India
Research Site
Vijayawada, Andhra Pradesh, India
Research Site
Patna, Bihar, India
Research Site
Ahmedabad, Gujarat, India
Research Site
Rajkot, Gujarat, India
Research Site
Surat, Gujarat, India
Research Site
Vadodara, Gujarat, India
Research Site
Gurgaon, Haryana, India
Research Site
Srinagar, Jammu and Kashmir, India
Research Site
Bangalore, Karnataka, India
Research Site
Bengaluru, Karnataka, India
Research Site
Mysore, Karnataka, India
Research Site
Kolenchery, Kerala, India
Research Site
Thrissur, Kerala, India
Research Site
Mumbai, Maharashtra, India
Research Site
Nashik, Maharashtra, India
Research Site
Pune, Maharashtra, India
Research Site
New Delhi, National Capital Territory of Delhi, India
Research Site
Delhi, New Delhi, India
Research Site
Bhubaneswar, Odisha, India
Research Site
Ludhiana, Punjab, India
Research Site
Mohali, Punjab, India
Research Site
Jaipur, Rajasthan, India
Research Site
Chennai, Tamil Nadu, India
Research Site
Coimbatore, Tamil Nadu, India
Research Site
Madurai, Tamil Nadu, India
Research Site
Hyderabad, Telangana, India
Research Site
Lucknow, Uttar Pradesh, India
Research Site
Noida, Uttar Pradesh, India
Research Site
Durgapur, West Bengal, India
Research Site
Kolkata, West Bengal, India
Related Publications (1)
Sawhney JPS, Dalal J, Mullasari A, Bansal S, Kahali D. Therapeutic experience of ticagrelor in Indian patients with acute coronary syndrome: A non-interventional, prospective, and observational study. Indian Heart J. 2019 Jul-Aug;71(4):344-349. doi: 10.1016/j.ihj.2019.08.001. Epub 2019 Aug 30.
PMID: 31779864DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
JP S Sawhney, MBBS, MD, DM
Sir Ganga Ram Hospital, Delhi
- STUDY DIRECTOR
Bhavesh P Kotak, MBBS MD
AstraZeneca Pharma India Ltd
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 31, 2015
First Posted
April 3, 2015
Study Start
April 27, 2015
Primary Completion
June 24, 2017
Study Completion
June 24, 2017
Last Updated
June 25, 2018
Record last verified: 2018-06